Global X Defense Tech ETF vs Viatris Inc — how do they compare? Global X Defense Tech ETF trades at $59.87 (market cap $6.29B), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: Viatris Inc is far larger — about 3.2× Global X Defense Tech ETF's market cap, and Viatris Inc pays a 2.75% dividend while Global X Defense Tech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Global X Defense Tech ETF for 44 Days and Viatris Inc for 57 Days on average.
| SHLD | VTRS | |
|---|---|---|
Market Cap | $6.29B | $20.03B |
Volume | 1,133,252 | 14,109,977 |
Sector | Sector/Thematic | Health |
52-Week High | $78.02 | $18.27 |
52-Week Low | $58.20 | $9.74 |
Typical Hold Time | 44 Days | 57 Days |
Enterprise Value | — | $32.15B |
Dividend Yield | — | 2.75% |
Signals from Pluang's Aura AI — not financial advice
SHLD (Global X Defense Tech ETF) trades at $59.19, up 0.77% today, but technical indicators show a bearish trend with moving averages signaling strong selling pressure. The ETF focuses on defense technology companies, benefiting from increased global defense spending and institutional accumulation. Recent news highlights growing investor interest as European allies push for rearmament, creating potential tailwinds for defense-focused portfolios.
The outlook remains cautiously optimistic given rising defense budgets and geopolitical tensions, though the bearish technical picture suggests near-term volatility. Investment opportunities center on exposure to cutting-edge defense innovation, while risks include political uncertainty and execution challenges in defense procurement cycles.
Viatris (VTRS) trades at $17.44, down 0.29% on the day, with a bullish technical outlook supported by moving averages and oversold RSI levels. The company has beaten earnings estimates for three consecutive quarters, though it faces profitability challenges with negative net margins. Recent positive developments include FDA approval for WAKIX in Japan and consistent dividend payments, while analyst consensus leans toward a buy rating with a $22.17 price target representing 27% upside potential.
The stock presents a value opportunity with reasonable P/S and P/B ratios, but investors must weigh strong cash generation against persistent profitability issues. Key catalysts include continued earnings beats and pipeline progress, while risks involve margin pressure and high debt levels. The current valuation disconnect between technical strength and fundamental challenges creates a balanced risk-reward profile for patient investors.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
SHLD tracks the Global X Defense Tech Index, targeting companies that lead the technological transformation of the defense sector. It focuses on pure-play innovators in cybersecurity, artificial intelligence, robotics, and advanced military systems, excluding traditional commercial aerospace to maintain a high level of thematic purity.
Read more on SHLD →Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →